Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

NCT07318805 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07318805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07318805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Recruiting
Start date
December 23, 2025
Completion date
April 14, 2030
Enrollment
260 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, colorectal cancer, metastatic breast cancer (hr+/ her2-), metastatic colorectal adenocarcinoma, triple negative breast cancer